This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion about the standard of care for Neuromyelitis Optica Spectrum Disorder and the potential of AstraZeneca's Ultomiris.

Ticker(s): AZN

Who's the expert?

Institution: SUNY Downstate Medical Center

  • Associate professor in the department of Neurology with a focus on Neuromuscular disease.
  • Currently follows 90 MG patients and has 14 years experience treating myasthenic patients in an MGFA recognized MG center.
  • Familiar with all emerging MG therapies and currently uses Solaris with his patients.

Interview Goal
Understanding the treatment options for Neuromyelitis Optica Spectrum Disorder and how Ultomiris fits in the space.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.